Cell & Gene Meeting on the Med is positioned as Europe’s premier conference for ATMPs. With more than 500 attendees expected, 40+ company presentations, 20+ panels and fireside chats, and over 1,000 partnering meetings, the event is designed to connect decision-makers, industry leaders, regulators, and innovators across the advanced therapies landscape.
Tuesday May 28, 1:30–2:00pm
Salone dei Cavalieri, Section 2&3
Jason C. Foster, CEO of Ori Biotech, sits down with Sebastian Honoré, rare disease dad, advocate, and CEO of the Cure Lowe Foundation.
Hear how Sebastian left his career at the Ministry of Finance to dedicate himself fully to developing a breakthrough gene therapy to address the root cause of Lowe syndrome, the ultra-rare condition his son Walther lives with.
Cure Lowe is one of the few patient-founded organizations running its own drug development program, through its wholly-owned biotech subsidiary Walther Therapeutics. Its kidney-targeted AAV gene therapy for Lowe syndrome and Dent disease type 2 is now progressing towards clinical trials.